|
業務類別
|
Drug Manufacturers - Specialty & Generic |
|
業務概覽
|
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx. |
| 公司地址
| 1A Burton Hills Boulevard, Suite 200, Nashville, TN, USA, 37215 |
| 電話號碼
| +1 615 733-4730 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.harrow.com |
| 員工數量
| 373 |
| Mr. Mark L. Baum |
Chief Executive Officer and Chairman of the Board |
美元 754.91K |
24/04/2026 |
| Mr. Randall E. Pollard |
Chief Accounting Officer |
-- |
02/03/2026 |
| Mr. Patrick W. Sullivan |
Chief Commercial Officer |
-- |
24/04/2026 |
| Mr. Andrew R. Boll |
President, Chief Financial Officer and Corporate Secretary |
美元 505.26K |
24/04/2026 |
| Mr. Francis William Mullery, Jr |
President and Chief Executive Officer, ImprimisRx Division |
美元 129.81K |
24/04/2026 |
| Mr. Amir H. Shojaei |
Chief Scientific Officer |
美元 441.35K |
24/04/2026 |
| Mr. Patrick William Sullivan |
Chief Commercial Officer |
-- |
02/02/2026 |
|
|
| Mr. Mark L. Baum |
Chief Executive Officer and Chairman of the Board |
24/04/2026 |
| Ms. Lauren P. Silvernail |
Independent Director |
24/04/2026 |
| Dr. Adrienne L. Graves,PhD |
Independent Director |
24/04/2026 |
| Mr. Perry J. Sternberg |
Lead Independent Director |
24/04/2026 |
|
|
|
|
